Ftbl Groups order some of their workers from Liberia amid Ebola outbreak Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administrationreported last week.Novartis, the pharmaceutical company that manufactures Pluvicto, outlined the causes behind the supply issuesin a le [url=https://www.stanleycup.com.se]stanley cup[/url] tterposted by the FDA last month.In the letter, the comp [url=https://www.stanley1913.com.es]stanley cup[/url] any said that it currently only manufactures Pluvicto in Italy in small ba [url=https://www.stanleymug.us]stanley cup[/url] tches, and is awaiting FDA approval on a new manufacturing site. That approval was expected to come in four to six months, Novartis said. We are operating our production site at full capacity to treat as many patients as possible, as quickly as possible. the company said. However, with a nuclear medicine like Pluvicto, there is no back-up supply that we can draw from when we experience a delay. Novartis said that any issues caused by weather or unplanned manufacturing events can cause delays. The company noted there is only a five-day window for the drug to reach the patient once its manufactured. When shipments of Pluvicto are delayed, or it has have to be remade, it creates a domino effect, the letter noted.The company said it is currently prioritizing patients who have received their first doses and are currently in the treatment process. Novartis said it will not take any new orders until there is clarity on the FDA s approval of its new manufacturing facility.Company spokesperson Julie Masow told The Wall Street JournalThursday that Novartis i Rxbr Oregon school shooting victim was loved by everybody [url=https://www.nikeair.fr]air max 1[/url] [url=https://www.adidas-yeezys.com.mx]yeezy[/url] [url=https://www.salomonschuhe.com.de]salomon[/url]